Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.9.3635

Tumor Infiltrating Lymphocytes in Ovarian Cancer  

Gasparri, Maria Luisa (Department of Gynecologic-Obstetrical and Urologic Sciences, "Sapienza" University of Rome)
Attar, Rukset (Department of Obstetrics and Gynecology, Yeditepe University Medical Faculty)
Palaia, Innocenza (Department of Gynecologic-Obstetrical and Urologic Sciences, "Sapienza" University of Rome)
Perniola, Giorgia (Department of Gynecologic-Obstetrical and Urologic Sciences, "Sapienza" University of Rome)
Marchetti, Claudia (Department of Gynecologic-Obstetrical and Urologic Sciences, "Sapienza" University of Rome)
Donato, Violante Di (Department of Gynecologic-Obstetrical and Urologic Sciences, "Sapienza" University of Rome)
Farooqi, Ammad Ahmad (Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College)
Papadia, Andrea (Department of Obstetrics and Gynecology, University Hospital of Berne and University of Berne)
Panici, Pierluigi Benedetti (Department of Gynecologic-Obstetrical and Urologic Sciences, "Sapienza" University of Rome)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.9, 2015 , pp. 3635-3638 More about this Journal
Abstract
Several improvements in ovarian cancer treatment have been achieved in recent years, both in surgery and in combination chemotherapy with targeting. However, ovarian tumors remain the women's cancers with highest mortality rates. In this scenario, a pivotal role has been endorsed to the immunological environment and to the immunological mechanisms involved in ovarian cancer behavior. Recent evidence suggests a loss of the critical balance between immune-activating and immune-suppressing mechanisms when oncogenesis and cancer progression occur. Ovarian cancer generates a mechanism to escape the immune system by producing a highly suppressive environment. Immune-activated tumor infiltrating lymphocytes (TILs) in ovarian tumor tissue testify that the immune system is the trigger in this neoplasm. The TIL mileau has been demonstrated to be associated with better prognosis, more chemosensitivity, and more cases of optimal residual tumor achieved during primary cytoreduction. Nowadays, scientists are focusing attention on new immunologically effective tumor biomarkers in order to optimize selection of patients for recruitment in clinical trials and to identify relationships of these biomarkers with responses to immunotherapeutics. Assessing this point of view, TILs might be considered as a potent predictive immunotherapy biomarker.
Keywords
Tumor infiltrating lymphocytes; cancer; apoptosis; target therapy;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Marchetti C, Imperiale L, Gasparri ML, et al (2012). Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin Investig Drugs, 21, 1575-84.   DOI
2 Mougiakakos D, Choudhury A, Lladser A, et al (2010). Regulatory T cells in cancer. Adv Cancer Res, 107, 57-117.   DOI
3 Napoletano C, Bellati F, Landi R, et al (2010). Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med, 14, 2748-59.   DOI
4 Nielsen JS, Sahota RA, Milne K, et al (2012). CD20+ tumorinfiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res, 18, 3281-92.   DOI
5 Papadia A, Morotti M. (2013). Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer, a review of the literature. Arch Gynecol Obstet, 287, 733-41.   DOI
6 Paroli M, Bellati F, Videtta M, et al (2014). Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells. Int J Cancer, 134, 1823-34.   DOI
7 Paulson KG, Carter JJ, Johnson LG, et al (2010).Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res, 70, 8388-97.   DOI
8 Raspollini MR, Castiglione F, Rossi Degl'innocenti D, et al (2005). Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol, 16, 590-6.   DOI
9 Salama M, Ormonde D, Quach T, et al (2010). Outcomes of endoscopic resection of large colorectal neoplasms, an Australian experience. J Gastroenterol Hepatol, 25, 84-9.   DOI
10 Santegoets SJ, Turksma AW, Suhoski MM, et al (2013). IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med, 11, 37.   DOI
11 Sato E, Olson SH, Ahn J, et al (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A, 102, 18538-43.   DOI
12 Schreiber RD, Old LJ, Smyth MJ et al (2011). Cancer immunoediting, integrating immunity's roles in cancer suppression and promotion. Science, 331, 1565-70.   DOI   ScienceOn
13 Tomsova M, Melichar B, Sedlakova I, et al (2008). Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol, 108, 415-20.   DOI
14 Webb JR, Milne K, Watson P, et al (2014). Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res, 20, 434-44.   DOI
15 Yigit R, Massuger LF, Figdor CG, et al (2010). Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol, 117, 366-72.   DOI
16 Zhang L, Conejo-Garcia JR, Katsaros D, et al (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med, 348, 203-13.   DOI
17 Zitvogel L, Kepp O, Kroemer G. (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol, 8, 151-60.   DOI
18 Heintz AP, Odicino F, Maisonneuve P, et al (2006). Carcinoma of the ovary. FIGO 26th Annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet, 95, 161-92.   DOI
19 Bachmayr-Heyda A, Aust S, Heinze G, et al (2013). Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium. BMC Cancer, 13, 422.   DOI
20 Bian J, Li B, Kou XJ, et al (2014). Clinical applicability of multi-tumor marker protein chips for diagnosing ovarian cancer. Asian Pac J Cancer Prev, 15, 8409-11.   DOI
21 Clarke B, Tinker AV, Lee CH, et al (2009). Intraepithelial T cells and prognosis in ovarian carcinoma, novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol, 22, 393-402.   DOI
22 Clemente CG, Mihm MC Jr, Bufalino R, et al (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 77, 1303-10.   DOI
23 Guo CL, Yang HC, Yang XH, et al (2012). Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma. Asian Pac J Cancer Prev, 13, 5909-13.   DOI
24 deLeeuw RJ, Kroeger DR, Kost SE, et al (2014). CD25 identifies a subset of CD4+FoxP3-TIL that are exhausted yet prognostically favorable in human ovarian cancer. Cancer Immunol Res, 2014.
25 Gasparri ML, Bellati F, Napoletano C, et al (2013). Interaction between Treg cells and angiogenesis, a dark double track. Int J Cancer, 132, 2469.   DOI
26 Giannakakis A, Karapetsas A, Dangaj D, et al (2014). Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer. Int J Biochem Cell Biol, 53, 389-98.   DOI
27 Hwang WT1, Adams SF, Tahirovic E, et al (2012). Prognostic significance of tumor-infiltrating T cells in ovarian cancer, a meta-analysis. Gynecol Oncol, 124, 192-8.   DOI
28 Jochems C1, Schlom J (2011). Tumor-infiltrating immune cells and prognosis, the potential link between conventional cancer therapy and immunity. Exp Biol Med, 236, 567-79.   DOI
29 Kroemer G1, Galluzzi L, Kepp O, et al (2013). Immunogenic cell death in cancer therapy. Annu Rev Immunol, 31, 51-72.   DOI
30 Leone Roberti Maggiore U, Bellati F, Ruscito I, Gasparri ML, et al (2013). Monoclonal antibodies therapies for ovarian cancer. Expert Opin Biol Ther, 13, 739-64.   DOI
31 Luo L, Dong LY, Yan QG. (2014) Research Progress in Applying Proteomics Technology to Explore Early Diagnosis Biomarkers of Breast Cancer, Lung Cancer and Ovarian Cancer. Asian Pac J Cancer Prev, 15, 8529-38.   DOI